PMID- 38243799 OWN - NLM STAT- MEDLINE DCOM- 20240304 LR - 20240509 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 52 IP - 3 DP - 2024 Mar TI - Impact of Wiberg Patellar Type on Outcomes and Survival Following Cell-Based Cartilage Repair for Patellar Chondral Lesions at Midterm Follow-up. PG - 705-709 LID - 10.1177/03635465231220028 [doi] AB - BACKGROUND: Cell-based cartilage repair procedures of the patellofemoral joint have less reliable outcomes than those of the tibiofemoral joint. No previous studies have evaluated the influence of patellar shape on cell-based cartilage repair outcomes. Patellar dysplasia may predispose patients to worse outcomes after cell-based cartilage repair. PURPOSE/HYPOTHESIS: The purpose of this study was to evaluate the relationship between Wiberg patellar type and outcomes after cell-based cartilage repair (autologous chondrocyte implantation or particulated juvenile allograft cartilage transplantation) for the treatment of patellar chondral lesions at a minimum 2-year follow-up. It was hypothesized that Wiberg classification of patellar shape would have no effect on patient-reported outcome measures (PROMs) or graft survival. STUDY DESIGN: Cohort study; Level of evidence, 3. METHODS: Patients undergoing autologous chondrocyte implantation or particulated juvenile allograft cartilage transplantation for full-thickness patellar chondral defects between 2016 and 2020 were retrospectively reviewed after institutional review board approval. The change in PROMs, including International Knee Documentation Committee (IKDC), Kujala, and Veterans RAND 12-item Health Survey Mental and Physical scores, from pre- to postoperatively and the percentage of patients who achieved the minimal clinically important difference (MCID) for IKDC and Kujala scores were compared for the Wiberg type A versus Wiberg type B versus Wiberg type C groups. The log-rank test was used to evaluate for differences in survival between subgroups. RESULTS: A total of 59 patients (63 knees) were included, with a mean age of 33.3 +/- 8.6 years, median body mass index of 26.0 (IQR, 21.8-30.2), and median follow-up time of 3.5 years (IQR, 2.6-4.2 years). In total, 26 (41%) patellae were Wiberg type A, 29 (46%) were Wiberg type B, and 8 (13%) were Wiberg type C. There were no differences between Wiberg type A versus Wiberg type B versus Wiberg type C groups with respect to change in PROMs from pre- to postoperatively or the percentage of patients who achieved the MCID for IKDC or Kujala scores (P > .05 for all). There were no differences in survival between groups (P = .45). CONCLUSION: Wiberg patellar type has no effect on patient-reported outcomes or graft survival at midterm follow-up. Patellar dysplasia should not be seen as a contraindication for cell-based cartilage repair procedures. FAU - Retzky, Julia S AU - Retzky JS AD - Hospital for Special Surgery, Sports Medicine Institute, New York, New York, USA. FAU - Thacher, Ryan R AU - Thacher RR AD - Hospital for Special Surgery, Sports Medicine Institute, New York, New York, USA. FAU - Palhares, Guilherme H AU - Palhares GH AD - Hospital for Special Surgery, Sports Medicine Institute, New York, New York, USA. FAU - Gomoll, Andreas H AU - Gomoll AH AUID- ORCID: 0000-0001-8600-5301 AD - Hospital for Special Surgery, Sports Medicine Institute, New York, New York, USA. FAU - Strickland, Sabrina M AU - Strickland SM AD - Hospital for Special Surgery, Sports Medicine Institute, New York, New York, USA. LA - eng GR - T32 AR078751/AR/NIAMS NIH HHS/United States PT - Journal Article DEP - 20240120 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 SB - IM MH - Humans MH - Young Adult MH - Adult MH - *Cartilage, Articular/surgery MH - Cohort Studies MH - Follow-Up Studies MH - Retrospective Studies MH - Chondrocytes/transplantation MH - Transplantation, Autologous OTO - NOTNLM OT - articular cartilage OT - imaging OT - knee OT - magnetic resonance OT - patella COIS- One or more of the authors has declared the following potential conflict of interest or source of funding: A.H.G. has received consulting fees from Vericel, Bioventus, Organogenesis, Smith & Nephew, Joint Restoration Foundation, Flexion Therapeutics, and Moximed; speaking fees from Pacira Therapeutics and Linvatec; honoraria from Vericel and Fidia Pharma USA; and royalties or license from Organogenesis and Smith & Nephew; and holds stock in Engage Uni. S.M.S. has received consulting fees from Vericel, Flexion Therapeutics, and Miach Orthopaedics; honoraria from Vericel and Joint Restoration Foundation; speaking fees from Smith & Nephew; hospitality payments from Bioventus, Aesculap Biologics, Zimmer Biomet Holdings, Fidia Pharma USA, DePuy Synthes Sales, Dynasplint Systems, Pacira Therapeutics, and Organogenesis; and a gift from Engage Uni. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto. EDAT- 2024/01/20 21:41 MHDA- 2024/03/04 06:45 CRDT- 2024/01/20 09:04 PHST- 2024/03/04 06:45 [medline] PHST- 2024/01/20 21:41 [pubmed] PHST- 2024/01/20 09:04 [entrez] AID - 10.1177/03635465231220028 [doi] PST - ppublish SO - Am J Sports Med. 2024 Mar;52(3):705-709. doi: 10.1177/03635465231220028. Epub 2024 Jan 20.